LCN-2 is proposed as an early biomarker of SAP [69], being several times higher in SAP as compared to mild AP (MAP) and showing 100% sensitivity and specificity in discriminating SAP from MAP during the first 48 hours. Here, LCN2 is linked to alkaline phosphatase measurement.